|
Commitments and Contingencies (Details Textual) (USD $)
|
0 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May 16, 2014
|
Apr. 01, 2014
|
May 31, 2014
sqft
|
Mar. 31, 2014
|
Jan. 30, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Jun. 18, 2012
|
Jan. 30, 2013
Licensee
|
Jan. 30, 2013
Exclusive License Of Multi Day Injectable Insulin In Us
|
Jan. 30, 2013
Phase Two B Clinical Studies For Multi Day Injectable Insulin
|
Jan. 30, 2013
Phase Three Clinical Studies For Multi Day Injectable Insulin
|
Jan. 30, 2013
Approval By Fda Or Emea To Allow Marketing and Sales Of Multi Day Injectable Insulin
|
Jan. 30, 2013
Twelve Month Cumulative Sales Of Multi Day Injectable Insulin
|
Nov. 06, 2014
Subsequent Event
|
Jul. 31, 2012
Advisory Agreement
|
Mar. 31, 2014
Consulting Agreement
|
Mar. 26, 2014
Amended and Restated Employment Agreement
|
Jul. 31, 2012
Minimum
Advisory Agreement
|
Jan. 30, 2013
Maximum
|
Jul. 31, 2012
Maximum
Advisory Agreement
|
Jun. 18, 2012
Chief Executive Officer
|
Dec. 31, 2012
Chief Executive Officer
|
Apr. 01, 2012
Chief Scientific Officer
|
|
| Initial salary paid | $ 230,000 | $ 230,000 | $ 275,000 | |||||||||||||||||||||
| Increase decrease in base salary | 390,000 | 350,000 | 295,000 | |||||||||||||||||||||
| Percentage of annual performance bonus | 40.00% | 40.00% | ||||||||||||||||||||||
| Sharebased compensation arrangement by sharebased payment award options vested percentage | 50.00% | |||||||||||||||||||||||
| Bonus paid | 40,000 | 275,000 | ||||||||||||||||||||||
| Minimum value of financing activities | 5,000,000 | 5,000,000 | ||||||||||||||||||||||
| Proceeds from issuance of stock option to purchase of common stock | 3,500,000 | |||||||||||||||||||||||
| Services agreement expenses | 20,000 | 500,000 | 9,000 | 100 | 700 | |||||||||||||||||||
| Term Of Lease | 72 months | |||||||||||||||||||||||
| Operating Leases, Rent Expense | 28,939 | 88,616 | 12,862 | |||||||||||||||||||||
| Payments Of Monthly Lease Adjusted Annually Percentage | 3.00% | |||||||||||||||||||||||
| Adjusted Triple Net Expense Of Lease Payments | 36,427 | |||||||||||||||||||||||
| Area of Land | 27,000 | |||||||||||||||||||||||
| Security Deposit | 750,000 | |||||||||||||||||||||||
| Stock Issued During Period, Shares, Issued for Services | 500,000 | |||||||||||||||||||||||
| Capital Lease Obligations | 8,060 | |||||||||||||||||||||||
| Payments to Acquire Businesses, Gross | 400,000 | |||||||||||||||||||||||
| Business Acquisition Purchases Price Allocation Assets Acquired | 100,000 | |||||||||||||||||||||||
| Business Acquisition Contingent Consideration At Fair Values | 2,000,000 | 2,000,000 | 5,000,000 | 10,000,000 | 25,000,000 | 44,000,000 | ||||||||||||||||||
| Business Acquisition Contingent Consideration Amount Payment Period | 30 days | 30 days | 30 days | 30 days | 90 days | |||||||||||||||||||
| Business Combination, Contingent Consideration Arrangements, Description | Two million dollars ($2,000,000) to be paid within 30 days after the exclusive license of the multi-day injectable insulin in the United States to a commercial pharmaceutical company. | Two million dollars ($2,000,000) related to the initiation of Phase 2b clinical studies for a multi-day injectable insulin, payable 30 days after the first dosing of a patient in a formal Phase 2b clinical study; | Five million dollars ($5,000,000) after the initiation of Phase 3 clinical studies for the multi-day injectable insulin by the Company or a licensee of the Company, payable 30 days after the first dosing of a patient in a formal Phase 3 clinical study. | Ten million dollars ($10,000,000) upon the approval by the FDA or EMEA to allow the marketing and sales of the multi-day injectable insulin by the Company or a licensee of the Company, payable 30 days after the receipt of the approval letter or notice from the FDA or EMEA. | Twenty five million dollars ($25,000,000) if the twelve month cumulative sales of the multi-day injectable insulin by the Company or a licensee of the Company reaches five hundred million dollars ($500,000,000) in any one given twelve consecutive month period, so long as such period occurs during the life of the patents included in the purchased assets, payable 90 days after the twelfth month in which sales equaled or exceeded five hundred million dollars. | |||||||||||||||||||
| Cumulative Sales Amount | 500,000,000 | |||||||||||||||||||||||
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset | $ 55,000 | |||||||||||||||||||||||